Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28187370 | 0.83 | CES2 (0.31) | EIF4A3CES2CES1CA1CA2 | |
| SCHEMBL3741113 | 0.78 | CES2 (0.50) | LMNACES2CES1KEAP1PPARG | |
| SCHEMBL20912575 | 0.77 | KDM4E (0.35) | LMNACA1CA2 | |
| SCHEMBL6902621 | 0.77 | SRC (0.36) | EIF4A3PTGS1PTGS2SLC1A3SLC1A2 | |
| SCHEMBL5084418 | 0.76 | PSEN1 (0.35) | LMNA | |
| SCHEMBL14661473 | 0.76 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL5085546 | 0.76 | CES2 (0.39) | PTGS1PTGS2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29009873 | 0.76 | SLC1A3 (0.38) | EIF4A3PTGS1PTGS2SLC1A3SLC1A2 | |
| SCHEMBL29653910 | 0.76 | CES2 (0.39) | PTGS1PTGS2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5085545 | 0.76 | CES2 (0.39) | PTGS1PTGS2SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913747-B2 | Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2021-02-09 | — | — | US | disclosed |
| US-20200157109-A1 | EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN THROUGH A VERY EFFECTIVE PREPARATION OF THE INTERMEDIATE 2,4,5-TRIFLUOROPHENYLACETIC ACID | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2020-05-21 | — | — | US | disclosed |
| EP-3424927-B1 | EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN THROUGH A VERY EFFECTIVE PREPARATION OF THE INTERMEDIATE 2,4,5-TRIFLUOROPHENYLACETIC ACID | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019007578-A1 | EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN THROUGH A VERY EFFECTIVE PREPARATION OF THE INTERMEDIATE 2,4,5-TRIFLUOROPHENYLACETIC ACID | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-10 | — | — | WO | disclosed |
| EP-3424927-A1 | EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN THROUGH A VERY EFFECTIVE PREPARATION OF THE INTERMEDIATE 2,4,5-TRIFLUOROPHENYLACETIC ACID | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-09 | — | — | EP | disclosed |
| CN-105254519-B | Synthesizing method of sitagliptin key intermediate | 常州吉恩药业有限公司 | 2017-05-17 | — | — | CN | disclosed |
| WO-2008078350-A2 | PROCESS FOR THE PREPARATION OF FLUOROPHENYLACETIC ACIDS AND DERIVATIVES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157109-A1 | EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN THROUGH A VERY EFFECTIVE PREPARATION OF THE INTERMEDIATE 2,4,5-TRIFLUOROPHENYLACETIC ACID | DPP4, DPP9, DPP7 | EIF4A3 253/4885PTGS1 4015/4885PTGS2 3918/4885 |
| US-10913747-B2 | Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid | DPP4, DPP9, DPP7 | EIF4A3 253/4885PTGS1 4015/4885PTGS2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.